DE69329247T2 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
DE69329247T2
DE69329247T2 DE69329247T DE69329247T DE69329247T2 DE 69329247 T2 DE69329247 T2 DE 69329247T2 DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T2 DE69329247 T2 DE 69329247T2
Authority
DE
Germany
Prior art keywords
csf
antagonists
directed
agonists
crystalization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329247T
Other languages
English (en)
Other versions
DE69329247D1 (de
Inventor
Jayvardhan Pandit
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Robert Halenbeck
Lisa Fear
Eric Taylor
Ralph Yamamoto
Andrew Bohm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California
Original Assignee
University of California
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Chiron Corp filed Critical University of California
Application granted granted Critical
Publication of DE69329247D1 publication Critical patent/DE69329247D1/de
Publication of DE69329247T2 publication Critical patent/DE69329247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69329247T 1992-06-09 1993-06-09 Kristallisierung von m-csf Expired - Lifetime DE69329247T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (2)

Publication Number Publication Date
DE69329247D1 DE69329247D1 (de) 2000-09-21
DE69329247T2 true DE69329247T2 (de) 2001-05-31

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329247T Expired - Lifetime DE69329247T2 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (de)
EP (2) EP0955365A3 (de)
JP (2) JPH08507916A (de)
AT (1) ATE195553T1 (de)
CA (1) CA2137793C (de)
DE (1) DE69329247T2 (de)
WO (1) WO1993025687A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2249007A1 (en) * 1996-03-14 1997-09-18 Takeshi Shibuya Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
AU2002325819B2 (en) 2001-07-11 2008-06-19 Maxygen, Inc. G-CSF Conjugates
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
EP1706137A2 (de) * 2004-01-21 2006-10-04 Chiron Corporation M-csf-muteine und deren verwendung
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
CA2607844C (en) 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
RS54596B1 (en) * 2009-12-10 2016-08-31 F. Hoffmann-La Roche Ag Antibodies Binding to Extracellular Domain 4 of Human CSF1R and Their Use
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
TR201900368T4 (tr) 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Csf1r'ye bağlanan antikorlar.
WO2013036829A1 (en) 2011-09-09 2013-03-14 Genentech, Inc Treatment of th17 mediated inflammatory diseases
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201501413YA (en) 2012-08-31 2015-03-30 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MX2016016664A (es) 2014-06-23 2017-03-20 Five Prime Therapeutics Inc Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
CN107567336B (zh) 2014-10-29 2021-12-31 戊瑞治疗有限公司 癌症的联合治疗
BR112017013111A2 (pt) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
DK3283527T3 (da) 2015-04-13 2021-03-08 Five Prime Therapeutics Inc Kombinationsterapi mod cancer
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
WO2018115051A1 (en) 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
JP2644794B2 (ja) * 1986-10-24 1997-08-25 カイロン コーポレイション 新規な型のコロニー刺激因子―１
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
JP2975109B2 (ja) * 1989-12-21 1999-11-10 ノボ ノルディスク アクティーゼルスカブ 酵素の結晶化方法
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech Inc Auswählen von agonisten und antagonisten von liganden

Also Published As

Publication number Publication date
EP0668914B1 (de) 2000-08-16
EP0955365A3 (de) 2000-12-20
ATE195553T1 (de) 2000-09-15
US5866114A (en) 1999-02-02
JP2004285076A (ja) 2004-10-14
CA2137793A1 (en) 1993-12-23
US6184354B1 (en) 2001-02-06
EP0955365A2 (de) 1999-11-10
CA2137793C (en) 2003-04-22
DE69329247D1 (de) 2000-09-21
WO1993025687A1 (en) 1993-12-23
JPH08507916A (ja) 1996-08-27
EP0668914A1 (de) 1995-08-30

Similar Documents

Publication Publication Date Title
DE69329247D1 (de) Kristallisierung von m-csf
BG102950A (en) Antibodies for ed-b domain of fibronectine, their structure and application
NO851516L (no) Krysstang-kvadrupolkilde for akustisk broennlogging.
ES2113368T3 (es) Antagonistas de serotonina.
DE68907527D1 (de) Laser-bohren von bauteilen.
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
DE69016304D1 (de) Agglomerieren von Teilchen.
DE69029165D1 (de) Reinigung von Kohlenwasserstofffraktionen
IT8819262A0 (it) Processo per la metallizzazione dimateriali fibrosi.
ES2135477T3 (es) Proceso de produccion de (s)-3-amino-1-pirrolidinas sustituidas.
DE69123970T2 (de) Ehv-4 glykoprotein vazin
ATE103594T1 (de) Fucosidase-inhibitoren.
ES2067541T3 (es) Mejoras en antagonistas de la serotonina y relacionadas con ellos.
TR199901395T2 (xx) Yeni karboksi ikameli siklik karboksamid t�revleri.
EP0480764A3 (en) Process to find stability of oil mixtures, including shale oil and fractions thereof
DE69504198T2 (de) Substituierte alkyldiaminderivate und ihre verwendung als tachykinin antagonisten
KR950700899A (ko) 히스타민 수용체 길항물질의 합성에 있어서 중간물질로써 유용한 4-피리딜과 4 피페리디닐아미다졸의 제조공정
IT1174473B (it) Procedimento per la produzione di polietelene di bassa densita'lineare
DE69015270D1 (de) Cyclische vinyloge N-hydroxy-N-methylharnstoffe verwendbar als 5-Lipoygenase-Inhibitoren.
DE69019301T2 (de) Herstellungsverfahren von Indolen.
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
CA1262906C (en) 3-(2-FUROYL)-5-ALCOXYCARBONYL-2,6-DIMETHYL-4-(2-NITROPHENYL)-1,4-DIHYDROPYRIDINES, CALCIUM ANTAGONISTS
DE3784877D1 (de) Herstellungsverfahren von 2,6-dichlorbenzylalkohol.
NO891681L (no) Fremgangsmaate for syntese av c5+ hydrokarboner.
EP0342422A3 (de) Verfahren zur Herstellung von 2',3'-Dideoxynucleosiden und dabei verwendete neue Zwischenprodukte

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, O, US